The Hindu Business Line : Aurobindo Pharma Q1 Net higher at Rs 36.21 cr

Aurobindo Pharma Ltd (APL) has reported a growth of 60 per cent in total revenues, 212 per cent in earnings before interest, depreciation, tax and amortisation (EBIDTA), and multi-fold growth in net profit for the first quarter of current fiscal ended June 30. As per the unaudited financial results approved by the APL board on Monday, the company posted a turnover of Rs 455.67 crore against Rs 284.24 crore in the corresponding quarter of previous fiscal, EBIDTA of Rs 83 crore (Rs 26.6 crore) and a net profit of Rs 36.21 crore (Rs 2.01 crore). This translates into an EPS of Rs 6.80 (Rs 0.39) on the expanded equity base of Rs 26.63 crore (Rs 25.38 crore).

In a press release here, the company has attributed the improved performance to the thrust on regulated markets and formulation businesses. The exports stood at Rs 251.59 crore (Rs 158.53 crore) during the period.

During the quarter under review, the company's formulations sales have grown by 305 per cent and constituted 23.8 per cent of total sales. The contribution of semi-synthetic penicillins (SSPs) stood at 23.5 per cent, cephalosporins 28.7 per cent, antivirals and other active pharmaceutical ingredients 23.9 per cent, reflecting a decisive improvement in the product mix.

The company's export sales have grown by 59 per cent and constituted 57.4 per cent of total sales. The exports have shown significant improvement across all the markets. The contribution of US stood at 31.4 per cent, Europe 23 per cent, Africa/CIS 14.1 per cent and Asia 31.5 per cent to the total exports.During the quarter under review, the company filed nine abbreviated new drug applications (ANDAs) and 12 drug master files (DMFs) in the USalone.

In addition to the US, the company said it has also ramped up the filings in other key regulated markets such as Europe.

The company raised $ 200-million through issue of zero coupon foreign currency convertible bonds (FCCBs) due 2011.

More Stories on : Pharmaceuticals | Financial Performance

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page